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Since the publication of our article [1], it has come to
our attention that we failed to include information for
two of the authors in the competing interests section.
Craig Richie has declared potential competing interests
with the following companies; Janssen, Eisai, Pfizer, Eli
Lilly, Roche Diagnostics, Boeringher Ingleheim, Novartis,
AC Immune, Ixico, Aridhia, Amgen, Berry Consultants,
Lundbeck, Sanofi, Quintiles (IQVIA) and Takeda. Jeremy
Issacs has declared potential competing interests with
the following companies; Roche and Merck & Co. The
full competing interests section for this article can be
found below.
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